Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Biomarker Diagnoses Acute Heart Failure

By LabMedica International staff writers
Posted on 06 May 2013
The biomarker, cluster of differentiation 146 (CD146), which can be measured in the blood, significantly improves the diagnosis of acute heart failure for patients with shortness of breath. More...


This biomarker provides clinicians with unique additional information allowing better treatment of this challenging group of patients and has the potential to improve the diagnostic accuracy of specific peptide tests.

Current clinical practice for triaging patients with shortness of breath includes the measurement of specific peptides: B-type natriuretic peptides (BNP) or N-terminal prohormone of brain natriuretic peptide (NT-proBNP). Despite the widespread use of these biomarkers, there is still room for improvement.

Scientists at French National Institute of Health and Medical Research (INSERM; Paris, France) have confirmed the performance of the CD146 biomarker (Pronota NV; Ghent, Belgium) in two independent studies totaling over 500 patients. Pronota identified the biomarker CD146, also known as the melanoma cell adhesion molecule (MCAM), from an unbiased proteomics effort.

Alexandre Mebazaa MD, PhD, the principal investigator for the validation studies, commented: "It is exciting to see that novel biomarkers with underlying biological processes completely different from currently used biomarkers can still be discovered and validated. This not only provides more insight into the underlying disease mechanism, it also gives the physician tools to improve the management and care of heart failure patients. Pronota's approach in this respect is unique and has proven to deliver on numerous occasions."

Katleen Verleysen, PhD, the CEO of Pronota, said, “Data from early verification and marker characterization studies were already highly exciting, but the recent independent validation studies exceeded our expectations and would not have been possible without the support of our network of key opinion leaders in the field. We anticipate launching this product in 2014, so that clinicians may get access to the tools they need to improve the treatment and care of their patients."


Related Links:
French National Institute of Health and Medical Research
Pronota NV


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.